These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 8426748)

  • 1. Characterization of Ras effector mutant interactions with the NF1-GAP related domain.
    Marshall MS; Hettich LA
    Oncogene; 1993 Feb; 8(2):425-31. PubMed ID: 8426748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ras effector loop mutations that dissociate p120GAP and neurofibromin interactions.
    Stang S; Bottorff D; Stone JC
    Mol Carcinog; 1996 Jan; 15(1):64-9. PubMed ID: 8561868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of neurofibromatosis type I gene product as an insoluble GTPase-activating protein toward ras p21.
    Hattori S; Maekawa M; Nakamura S
    Oncogene; 1992 Mar; 7(3):481-5. PubMed ID: 1549362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Farnesyltransferase inhibitors block the neurofibromatosis type I (NF1) malignant phenotype.
    Yan N; Ricca C; Fletcher J; Glover T; Seizinger BR; Manne V
    Cancer Res; 1995 Aug; 55(16):3569-75. PubMed ID: 7627966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of the neurofibromatosis type 1 (NF1) GAP-related domain by site-directed mutagenesis.
    Gutmann DH; Boguski M; Marchuk D; Wigler M; Collins FS; Ballester R
    Oncogene; 1993 Mar; 8(3):761-9. PubMed ID: 8437860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The GTPase-activating NF1 fragment of 91 amino acids reverses v-Ha-Ras-induced malignant phenotype.
    Nur-E-Kamal MS; Varga M; Maruta H
    J Biol Chem; 1993 Oct; 268(30):22331-7. PubMed ID: 8226742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suppression of oncogenic Ras by mutant neurofibromatosis type 1 genes with single amino acid substitutions.
    Nakafuku M; Nagamine M; Ohtoshi A; Tanaka K; Toh-e A; Kaziro Y
    Proc Natl Acad Sci U S A; 1993 Jul; 90(14):6706-10. PubMed ID: 8341688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [NF1 (neurofibromatosis type 1)].
    Maruta H; Nur-e-Kamal
    Gan To Kagaku Ryoho; 1997 Sep; 24(11):1422-6. PubMed ID: 9309135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reconstitution of the NF1 GAP-related domain in NF1-deficient human Schwann cells.
    Thomas SL; Deadwyler GD; Tang J; Stubbs EB; Muir D; Hiatt KK; Clapp DW; De Vries GH
    Biochem Biophys Res Commun; 2006 Sep; 348(3):971-80. PubMed ID: 16908010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppression of a human colon cancer cell line by introduction of an exogenous NF1 gene.
    Li Y; White R
    Cancer Res; 1996 Jun; 56(12):2872-6. PubMed ID: 8665528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel, activated RAS mutations alter protein-protein interactions.
    Dalley BK; Cannon JF
    Oncogene; 1996 Sep; 13(6):1209-20. PubMed ID: 8808695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21.
    Martin GA; Viskochil D; Bollag G; McCabe PC; Crosier WJ; Haubruck H; Conroy L; Clark R; O'Connell P; Cawthon RM
    Cell; 1990 Nov; 63(4):843-9. PubMed ID: 2121370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppression of c-ras transformation by GTPase-activating protein.
    Zhang K; DeClue JE; Vass WC; Papageorge AG; McCormick F; Lowy DR
    Nature; 1990 Aug; 346(6286):754-6. PubMed ID: 2201922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of the potential pathogenicity of missense mutations identified in the GTPase-activating protein (GAP)-related domain of the neurofibromatosis type-1 (NF1) gene.
    Thomas L; Richards M; Mort M; Dunlop E; Cooper DN; Upadhyaya M
    Hum Mutat; 2012 Dec; 33(12):1687-96. PubMed ID: 22807134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differences in the interaction of p21c-Ha-ras-GMP-PNP with full-length neurofibromin and GTPase-activating protein.
    DiBattiste D; Golubic M; Stacey D; Wolfman A
    Oncogene; 1993 Mar; 8(3):637-43. PubMed ID: 8437847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential expression of two types of the neurofibromatosis type 1 (NF1) gene transcripts related to neuronal differentiation.
    Nishi T; Lee PS; Oka K; Levin VA; Tanase S; Morino Y; Saya H
    Oncogene; 1991 Sep; 6(9):1555-9. PubMed ID: 1923522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of Ras/Raf interaction by anti-oncogenic mutants of neurofibromin, the neurofibromatosis type 1 (NF1) gene product, in cell-free systems.
    Mori S; Satoh T; Koide H; Nakafuku M; Villafranca E; Kaziro Y
    J Biol Chem; 1995 Dec; 270(48):28834-8. PubMed ID: 7499408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A conserved alternative splice in the von Recklinghausen neurofibromatosis (NF1) gene produces two neurofibromin isoforms, both of which have GTPase-activating protein activity.
    Andersen LB; Ballester R; Marchuk DA; Chang E; Gutmann DH; Saulino AM; Camonis J; Wigler M; Collins FS
    Mol Cell Biol; 1993 Jan; 13(1):487-95. PubMed ID: 8417346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IQGAP1, a calmodulin-binding protein with a rasGAP-related domain, is a potential effector for cdc42Hs.
    Hart MJ; Callow MG; Souza B; Polakis P
    EMBO J; 1996 Jun; 15(12):2997-3005. PubMed ID: 8670801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients.
    Basu TN; Gutmann DH; Fletcher JA; Glover TW; Collins FS; Downward J
    Nature; 1992 Apr; 356(6371):713-5. PubMed ID: 1570015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.